 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Biomarker Insights. The article, entitled Detecting Prostate Cancer Using Pattern Recognition Neural Networks with Flow Cytometry-Based Immunophenotyping in At-Risk Men, supports the use of Anixas CchekTM early cancer detection technology as a tool to improve prostate cancer detection and reduce unnecessary biopsies. 